Pharmaceuticals News

Asimov will use its CHO Edge System to develop a high-titer cell line for Kaigene’s therapeutic candidate that selectively degrades pathogenic antibodies.

Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS...

PRESS RELEASE CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor LONDON – 18 August 2026 -- CHARM Therapeutics...

Company announcement no. 31 - 2618 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026....

Total revenue increases by 14% to CHF 119 millionOperating profit increases by 32% to CHF 32 million and net profit by 77% to CHF 28 millionFosmanogepix phase 3 program on track for data readout and...

14 % Wachstum des Gesamtumsatzes auf CHF 119 Mio.32 % Steigerung des Betriebsgewinns auf CHF 32 Mio. und 77 % Steigerung des Gewinns auf CHF 28 Mio.Phase-3-Programm mit Fosmanogepix auf Kurs für die...

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company...

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company’s Board of...

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...